AVE(SH:688067) Sou Hu Cai Jing·2025-07-07 11:24Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aiwei Technology in the medical device industry, noting its high PE ratio compared to industry averages [1][2] - As of July 7, Aiwei Technology's stock closed at 21.69 yuan, with a rolling PE ratio of 61.22 times and a total market capitalization of 1.475 billion yuan [1] - The average PE ratio for the medical device industry is 51.42 times, with a median of 37.44 times, positioning Aiwei Technology at the 90th rank within the industry [1][2] Group 2 - The company specializes in the research, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - As of December 31, 2024, Aiwei Technology and its subsidiaries hold 259 authorized patents (including 97 domestic invention patents and 18 overseas patents) and 30 software copyrights [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, a year-on-year increase of 24.63%, with a gross profit margin of 55.59% [1]